"Anaplastic Lymphoma Kinase (ALK) Inhibitor - Pipeline Insight, 2020" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the mechanism of action. A detailed picture of the Anaplastic Lymphoma Kinase (ALK) Inhibitor pipeline landscape is provided, which includes the topic overview and Anaplastic Lymphoma Kinase (ALK) Inhibitor mechanism of action. The assessment part of the report embraces, in-depth Anaplastic Lymphoma Kinase (ALK) Inhibitor commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes the product description, mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
The report provides insights into:
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university web sites and industry-specific third party sources, etc.
This report provides a comprehensive commercial assessment of therapeutic drugs that have been included, which comprises of collaborations, licensing, acquisition deal value trends. The sub-segmentation is described in the report, which provides company-company collaborations (licensing/partnering), company-academia collaborations, and acquisition analysis in both graphical and tabulated form.
The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this mechanism of action.
1. Report Introduction
2. Anaplastic Lymphoma Kinase (ALK) Inhibitor
2.1. Anaplastic Lymphoma Kinase (ALK) Inhibitor Overview
2.2. Anaplastic Lymphoma Kinase (ALK) Inhibitor Classification
2.3. Anaplastic Lymphoma Kinase (ALK) Inhibitor Structure
2.4. Anaplastic Lymphoma Kinase (ALK) Inhibitor Mechanism of Action
2.5. Anaplastic Lymphoma Kinase (ALK) Inhibitor Application
3. Anaplastic Lymphoma Kinase (ALK) Inhibitor - DelveInsight's Analytical Perspective
3.1. In-depth Commercial Assessment
3.1.1. Anaplastic Lymphoma Kinase (ALK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
3.1.1.1. Assessment Summary
3.1.2. Anaplastic Lymphoma Kinase (ALK) Inhibitor Collaboration Deals
3.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis
3.1.2.2. Company-University Collaborations (Licensing/Partnering) Analysis
3.1.2.3. Anaplastic Lymphoma Kinase (ALK) Inhibitor Acquisition Analysis
4. Therapeutic Assessment
4.1. Clinical Assessment of Pipeline Drugs
4.1.1. Assessment by Phase of Development
4.1.2. Assessment by Product Type (Mono/Combination)
4.1.2.1. Assessment by Stage and Product Type
4.1.3. Assessment by Route of Administration
4.1.3.1. Assessment by Stage and Route of Administration
4.1.4. Assessment by Molecule Type
4.1.4.1. Assessment by Stage and Molecule Type
4.1.5. Assessment by MOA
4.1.5.1. Assessment by Stage and MOA
4.1.6. Assessment by Target
4.1.6.1. Assessment by Stage and Target
5. Late Stage Products (Phase-III)
6. Mid Stage Products (Phase-II)
7. Early Stage Products (Phase-I)
8. Pre-clinical Products and Discovery Stage Products
9. Inactive Products
10. Dormant Products
11. Discontinued Products
12. Anaplastic Lymphoma Kinase (ALK) Inhibitor Product Profiles
12.1. Drug Name: Company
12.1.1. Product Description
12.1.1.1. Product Overview
12.1.1.2. Mechanism of action
12.1.2. Research and Development
12.1.2.1. Clinical Studies
12.1.3. Product Development Activities
12.1.3.1. Collaboration
12.1.3.2. Agreements
12.1.3.3. Acquisition
12.1.3.4. Patent Detail
12.1.4. Tabulated Product Summary
12.1.4.1. General Description Table
Detailed information in the report
13. Anaplastic Lymphoma Kinase (ALK) Inhibitor Key Companies
14. Anaplastic Lymphoma Kinase (ALK) Inhibitor Key Products
15. Dormant and Discontinued Products
15.1. Dormant Products
15.1.1. Reasons for being dormant
15.2. Discontinued Products
15.2.1. Reasons for the discontinuation
16. Anaplastic Lymphoma Kinase (ALK) Inhibitor - Unmet Needs
17. Anaplastic Lymphoma Kinase (ALK) Inhibitor - Future Perspectives
18. Anaplastic Lymphoma Kinase (ALK) Inhibitor Analyst Review
19. Appendix
20. Report Methodology
20.1. Secondary Research
20.2. Expert Panel Validation
Table 1 : Assessment Summary
Table 2 : Company-Company Collaborations (Licensing/Partnering) Analysis
Table 3 : Anaplastic Lymphoma Kinase (ALK) Inhibitor Acquisition Analysis
Table 4 : Assessment by Phase of Development
Table 5 : Assessment by Product Type (Mono/Combination)
Table 6 : Assessment by Stage and Product Type
Table 7 : Assessment by Route of Administration
Table 8 : Assessment by Stage and Route of Administration
Table 9 : Assessment by Molecule Type
Table 10 : Assessment by Stage and Molecule Type
Table 11 : Assessment by MOA
Table 12 : Assessment by Stage and MOA
Table 13 : Assessment by Target
Table 14 : Assessment by Stage and Target
Table 15 : Late Stage Products (Phase-III)
Table 16 : Mid Stage Products (Phase-II)
Table 17 : Early Stage Products (Phase-I)
Table 18 : Pre-clinical and Discovery Stage Products
Table 19 : Inactive Products
Table 20 : Dormant Products
Table 21 : Discontinued Products
Figure 1 : Structure
Figure 2 : Mechanism
Figure 3 : Anaplastic Lymphoma Kinase (ALK) Inhibitor companies collaborations, Licensing, Acquisition Deal Value Trends
Figure 4 : Company-Company Collaborations (Licensing/Partnering) Analysis
Figure 5 : Anaplastic Lymphoma Kinase (ALK) Inhibitor Acquisition Analysis
Figure 6 : Assessment by Phase of Development
Figure 7 : Assessment by Product Type (Mono/Combination)
Figure 8 : Assessment by Stage and Product Type
Figure 9 : Assessment by Route of Administration
Figure 10 : Assessment by Stage and Route of Administration
Figure 11 : Assessment by Molecule Type
Figure 12 : Assessment by Stage and Molecule Type
Figure 13 : Assessment by MOA
Figure 14 : Assessment by Stage and MOA
Figure 15 : Late Stage Products (Phase-III)
Figure 16 : Mid Stage Products (Phase-II)
Figure 17 : Early Stage Products (Phase-I)
Figure 18 : Pre-clinical and Discovery Stage Products
Figure 19 : Inactive Products
Figure 20 : Dormant Products
Figure 21 : Discontinued Products
Figure 22 : Unmet Needs
